BioSpace News Archive

CVRx, Inc. announced the closing of its initial public offering of 8,050,000 shares of its common stock at a public offering price of $18.00 per share, which includes 1,050,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares, for total gross proceeds from the offering, before deducting the underwriting discount and other offering expenses payable by CVRx, of approximately $144.9 million.

ObsEva SA announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.

MISSISSAUGA, ON, July 2, 2021 /PRNewswire/ - Covalon Technologies Ltd., an advanced medical technologies company, announced the results of the matters voted upon at its Fiscal 2020 Annual and Special Meeting of Shareholders held June 30th, 2021.

Solid Biosciences Inc., a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced the grant of an inducement award to its newly appointed Senior Vice President, Clinical Development, Roxana Dreghici.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today notified regulatory agencies, institutional review boards, and investigators that effective immediately it is voluntarily pausing AROENaC1001, a Phase 1/2 clinical study of ARO-ENaC, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with cystic fibrosis (CF)

Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) (“ZIVO” and the “Company”), a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates originally derived from proprietary algal cultures, today announced the closing of the sale of an additional 150,000 shares of common stock,

Tiziana Life Sciences plc, a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, announces that the Forms 20-F and F-6 filed by Accustem Sciences Limited with the SEC have been declared effective, enabling the completion of the in specie distribution and spin out of Accustem Sciences Limited.